Ninth Circuit: Unlike CUTSA, DTSA Does Not Require a Plaintiff to Identify Their Trade Secrets With Particularity from the Start

November 14, 2025

Reading Time : 3 min

The Ninth Circuit recently reversed a district court’s decision to strike a plaintiff’s trade secret claims under the Defend Trade Secrets Act (DTSA) at the discovery stage. In doing so, the Ninth Circuit made clear that under the DTSA, whether a party defined their trade secret with sufficient particularity is a question of fact that generally does not lend itself to resolution in the absence of at least some discovery. This ruling contrasts with the California Uniform Trade Secrets Act (CUTSA), which requires a party to define their trade secrets with reasonable particularity before commencing discovery.

Here, plaintiff Quintara alleged that defendant Ruifeng misappropriated its trade secrets under the DTSA. Although the case was brought in California, Quintara did not raise any allegations under the CUTSA. Early in the discovery period, Ruifeng moved for a protective order, seeking to halt discovery until Quintara identified its alleged trade secrets with greater particularity. The district court, citing disclosure standards in the CUTSA, ordered Quintara to, among other things, identify each precise claimed trade secret with a list of their elements. Quintara responded by filing a more detailed trade secret disclosure, but again Ruifeng challenged its sufficiency, and at the recommendation of the district court, moved to strike the disclosure. The district court granted Ruifeng’s motion as to nine of the 11 trade secrets, finding that the disclosure failed to satisfy the particularity requirements of the CUTSA. After a jury returned a verdict in Ruifeng’s favor on the one remaining trade secret that Quintara chose to try, Quintara appealed the district court’s decision on the motion to strike.

On appeal, the Ninth Circuit held that the district court abused its discretion by striking, and functionally dismissing, Quintara’s trade secrets without sufficient discovery. The court first noted the “delicate problem” of conducting a trade secret case: trade secrets “derive their value from nondisclosure,” but proving possession of a trade secret necessarily requires disclosure. In other words, defendants have the right to know what they are being accused of and to get the evidence needed to defend themselves, but both sides may reasonably be cautious about unnecessarily providing a rival with overly precise details of their proprietary information. Because of this, trade secret discovery is often an “iterative process” where trade secret disclosures are refined as discovery proceeds.

After recognizing the general difficulties that arise in every trade secret case, the Ninth Circuit turned to the specifics of this case. In particular, the court held the district court erred when it attempted to apply the rules that govern CUTSA claims in a case where only DTSA claims were alleged. Although the CUTSA requires that a plaintiff identify a trade secret with “reasonable particularity” before discovery, the DTSA contains no such express timing requirements. Additionally, unlike the CUTSA’s reasonable particularity requirement, the sufficient particularity requirement of the DTSA is a question of fact. In early-stage discovery, “a DTSA trade-secret claim will rarely be dismissible as a discovery sanction.” Rather, the issue of whether a trade secret has been adequately defined under the DUTSA is more appropriate at the summary judgement or trial stage. The court further explained that while the CUTSA’s “reasonable particularity” rule has been applied in cases having both DTSA and CUTSA claims, here, Quintara brought claims under only the DTSA. Thus, it was an abuse of discretion to apply the CUTSA standard and strike the trade secrets at such an early stage of the case.

The court additionally held that the Federal Rules of Civil Procedure did not authorize the district court to strike Quintara’s claims as a sanction for failure to comply with its discovery requirements. Under Rule 12(f), a court may “strike from a pleading an insufficient defense or any redundant, immaterial, impertinent, or scandalous matter.” Even when treating the trade secret disclosure as a “pleading” to which Rule 12(f) would apply, the Ninth Circuit held that the disclosures were not an “insufficient defense,” or any other category of strikable material.

Rules 16, 26 and 37 give district courts broad discretion over pretrial matters. Nevertheless, dismissals based on a failure to comply with a pretrial order are a harsh penalty to be given only in “extreme circumstances.” Here, the short delay in discovery, lack of prejudice to Ruifeng, public policy favoring disposition of the case on its merits rather than through functional dismissal, and the district court’s lack of consideration of alternatives all weighed against dismissal. The court therefore reversed the district court’s order striking Quintara’s trade secrets and remanded the case.

Practice Tip: In cases where trade secrets may be alleged under multiple statutes, parties should be aware of the differing disclosure requirements and the implications they may have for early dismissal of a suit. The DTSA may provide a more favorable framework to obtain discovery early in a suit where there are concerns regarding disclosure of trade secrets.

Quintara Biosciences, Inc. v. Ruifeng Biztech, Inc., No. 23-16093 (9th Cir. Aug. 12, 2025) (Johnstone, J.)

Share This Insight

Previous Entries

IP Newsflash

November 14, 2025

The Ninth Circuit recently reversed a district court’s decision to strike a plaintiff’s trade secret claims under the Defend Trade Secrets Act (DTSA) at the discovery stage. In doing so, the Ninth Circuit made clear that under the DTSA, whether a party defined their trade secret with sufficient particularity is a question of fact that generally does not lend itself to resolution in the absence of at least some discovery. This ruling contrasts with the California Uniform Trade Secrets Act (CUTSA), which requires a party to define their trade secrets with reasonable particularity before commencing discovery.

...

Read More

IP Newsflash

November 11, 2025

The Federal Circuit recently vacated a summary judgment ruling of invalidity, holding that the district court erred in applying preclusive effect to the Patent Trial and Appeal Board’s unpatentability findings regarding other claims in the same patent. In doing so, the Federal Circuit reiterated that issue preclusion does not apply where the prior factual determinations were made under a lower standard of proof.

...

Read More

IP Newsflash

November 3, 2025

The Federal Circuit recently clarified the requirement for work disclosed in a reference to qualify as “by another” under pre-AIA Sections 102(a) and (e), holding that there must be complete inventive identity between the information disclosed in the asserted reference and the inventors named on the relevant patent. 

...

Read More

IP Newsflash

October 31, 2025

The District Court for the Northern District of California recently granted a defendant’s motion to bifurcate, ordering that issues related to PGR estoppel should be decided in a bench trial, while the remaining issues in the case should proceed to a jury trial.

...

Read More

IP Newsflash

October 31, 2025

The Northern District of Iowa recently held that a defendant’s motion for partial summary judgment of invalidity was barred after the PTAB issued final written decisions, regardless of when the motion was filed. The defendant filed its motion before the final written decisions were issued, but the court rejected the defendant’s argument that the timing of the motion insulated it from estoppel.

...

Read More

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.